C3 (Complement C3)
Central component of the complement system; key mediator of innate immunity and inflammation
Gene Information Card
| Symbol | C3 |
|---|---|
| Full Name | Complement C3 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 718 ncbi.nlm.nih.gov/gene/718 |
| Ensembl ID | ENSG00000125730 |
| UniProt ID | P01024 |
| OMIM ID | 120700 |
| HGNC ID | 1318 |
| Aliases | AHUS5, ARMD9, C3a, C3b, CPAMD1, HEL-S-62p |
Description
The C3 gene encodes complement component 3, a central protein of the complement system. C3 is synthesized primarily by the liver and plays a critical role in innate immunity by opsonizing pathogens, promoting inflammation, and forming the membrane attack complex. Proteolytic cleavage generates active fragments C3a (anaphylatoxin) and C3b (opsonin). Mutations in C3 are associated with atypical hemolytic uremic syndrome, age-related macular degeneration, and C3 glomerulopathy.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Atypical hemolytic uremic syndrome (aHUS) | Loss-of-function or gain-of-function mutations in C3 lead to dysregulated complement activation, causing endothelial damage and microvascular thrombosis. | ClinVar; OMIM #612925 |
| Age-related macular degeneration (AMD) | Common variants (e.g., rs2230199, R102G) alter C3 function, increasing complement deposition in the retina. | OMIM #603075; NCBI Gene |
| C3 glomerulopathy (C3G) | Deficiency or mutations in C3 result in uncontrolled alternative pathway activation and glomerular deposition of C3 fragments. | OMIM #613779; ClinVar |
| Complement C3 deficiency | Biallelic loss-of-function mutations cause recurrent bacterial infections and immune complex disease. | OMIM #120700; ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 68.2 | High |
| Adipose tissue | 12.5 | Medium |
| Lung | 8.3 | Medium |
| Kidney | 6.1 | Low |
| Brain | 1.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 (liver) | 45.3 | High expression |
| A549 (lung) | 9.8 | Moderate expression |
| HEK293 (kidney) | 5.4 | Low expression |
| THP-1 (monocyte) | 3.1 | Low expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.304C>T (p.Arg102Gly) | SNV | Common (allele frequency ~0.2 in Europeans) | Alters C3 function; risk factor for AMD |
| c.481C>T (p.Arg161Trp) | SNV | Rare | Associated with aHUS; impaired regulation |
| c.2230G>A (p.Gly744Arg) | SNV | Rare | Associated with C3 glomerulopathy; gain of function |
| c.3700G>A (p.Glu1234Lys) | SNV | Rare | Associated with aHUS; loss of regulation |
Mutation functional classification
Loss of Function (LOF)
Biallelic loss-of-function mutations (e.g., nonsense, frameshift) cause complete C3 deficiency, leading to recurrent infections.
Gain of Function (GOF)
Missense mutations such as p.Gly744Arg enhance C3 convertase activity, predisposing to C3 glomerulopathy.
Dominant Negative (DN)
Some missense variants (e.g., p.Arg161Trp) may act as dominant negatives by impairing C3b inactivation, contributing to aHUS.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Complement cascade (Reactome: R-HSA-166658)
• Alternative complement activation (Reactome: R-HSA-173736)
• Classical antibody-mediated complement activation (Reactome: R-HSA-173623)
• Lectin pathway of complement activation (Reactome: R-HSA-166662)
• Immune system (KEGG: hsa04610)
Protein Summary
Complement C3 is a 1663-amino-acid glycoprotein (185 kDa) synthesized as a single-chain precursor, then proteolytically processed into alpha and beta chains linked by disulfide bonds. It is the most abundant complement protein in serum (~1.3 mg/mL). C3 is cleaved by C3 convertase into C3a (anaphylatoxin) and C3b (opsonin). C3b covalently attaches to pathogen surfaces, marking them for phagocytosis, and initiates the formation of the membrane attack complex. C3a promotes inflammation via chemotaxis and mast cell degranulation. Regulation by factors H and I prevents excessive activation. Mutations disrupting regulation lead to renal and retinal diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NADC30M、NADCGP5、PorB Overexpression CHO-K1 Stable Cell Line | EDC90045 | Hamster | Details Get a Quote | |
| ZC3H4 Knockout HEK293 Cell Line | EDJ-KQ170 | Human | 23211 | Details Get a Quote |
| SLC38A9 Knockout HEK293T Cell Line | EDJ-KQ214 | Human | 153129 | Details Get a Quote |
| LAMC3 Knockout HEK293 Cell Line | EDJ-KQ259 | Human | 10319 | Details Get a Quote |
| NFATC3 Knockout HEK293 Cell Line | EDJ-KQ714 | Human | 4775 | Details Get a Quote |
| G6PC3 Knockout HEK293 Cell Line | EDJ-KQ797 | Human | 92579 | Details Get a Quote |
| MAP1LC3B2 Knockout HEK293 Cell Line | EDJ-KQ858 | Human | 643246 | Details Get a Quote |
| VDAC3 Knockout HEK293 Cell Line | EDJ-KQ972 | Human | 7419 | Details Get a Quote |
| WFDC3 Knockout HEK293 Cell Line | EDJ-KQ1028 | Human | 140686 | Details Get a Quote |
| ARRDC3 Knockout HEK293 Cell Line | EDJ-KQ1095 | Human | 57561 | Details Get a Quote |
| SLC38A9 Knockout HEK293 Cell Line | EDJ-KQ1142 | Human | 153129 | Details Get a Quote |
| SHC3 Knockout HEK293 Cell Line | EDJ-KQ1207 | Human | 53358 | Details Get a Quote |
| RAC3 Knockout HEK293 Cell Line | EDJ-KQ1238 | Human | 5881 | Details Get a Quote |
| SLC39A13 Knockout HEK293 Cell Line | EDJ-KQ1374 | Human | 91252 | Details Get a Quote |
| BBC3 Knockout HEK293 Cell Line | EDJ-KQ1394 | Human | 27113 | Details Get a Quote |
Displaying Records 1 To 15 Of 1053 Records
- 1
- 2
- ...
- 69
- 70
- Next Page »